Profile data is unavailable for this security.
About the company
Vetoquinol SA is a France-based company that specializes in the research, development, manufacture, marketing and sale of veterinary drugs and products. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The Company markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. It trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
- Revenue in EUR (TTM)537.47m
- Net income in EUR47.14m
- Incorporated1962
- Employees2.52k
- LocationVetoquinol SASainte-Anne 34 rue du CheneBp 189, Lure CedexLURE 70204FranceFRA
- Phone+33 384625555
- Fax+33 384625556
- Websitehttps://www.vetoquinol.com/fr
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry Co., Ltd | 712.69m | 11.55m | 948.31m | 4.33k | 82.14 | 1.32 | -- | 1.33 | 0.0861 | 0.0861 | 5.31 | 5.37 | 0.6127 | 4.56 | 3.76 | 1,254,216.00 | 0.7085 | 6.23 | 1.00 | 9.01 | 16.42 | 24.29 | 1.16 | 8.69 | 1.54 | -- | 0.1909 | 31.20 | -8.24 | 4.04 | -26.73 | -0.6127 | 24.20 | -3.77 |
| Phibro Animal Health Corp | 994.03m | 16.53m | 957.73m | 1.94k | 58.00 | 3.90 | 18.78 | 0.9635 | 0.4293 | 0.4293 | 25.82 | 6.38 | 1.08 | 2.60 | 6.75 | 539,568.10 | 1.80 | 3.93 | 2.20 | 4.90 | 31.47 | 31.18 | 1.66 | 3.77 | 1.69 | 2.20 | 0.6472 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Shilpa Medicare Ltd | 133.11m | 5.03m | 960.07m | 931.00 | 174.82 | -- | 55.79 | 7.21 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Procter & Gamble Health Ltd | 130.39m | 24.48m | 960.79m | 1.41k | 39.27 | -- | 34.96 | 7.37 | 131.11 | 131.11 | 698.31 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Vetoquinol SA | 537.47m | 47.14m | 986.20m | 2.52k | 20.83 | 1.81 | 13.54 | 1.83 | 3.98 | 3.98 | 45.42 | 45.89 | 0.793 | 2.34 | 5.83 | 216,459.50 | 6.95 | 7.09 | 8.58 | 9.40 | 48.81 | 61.27 | 8.77 | 8.84 | 1.91 | -- | 0.037 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| Jinyu Bio-Technology Co Ltd | 177.33m | 21.66m | 997.77m | 1.65k | 45.70 | 1.40 | -- | 5.63 | 0.1484 | 0.1484 | 1.21 | 4.84 | 0.197 | 2.10 | 1.62 | 816,227.80 | 2.36 | 4.82 | 2.74 | 5.68 | 54.60 | 58.78 | 11.97 | 19.91 | 3.12 | -- | 0.0079 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 728.16m | 216.58m | 1.01bn | 4.89k | 4.66 | 0.8854 | 4.01 | 1.38 | 2.02 | 2.02 | 6.78 | 10.61 | 0.4272 | 2.50 | 3.74 | 1,292,076.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 50.79 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Industri Jamu dn Frms Sd Mncl Tbk PT | 229.47m | 68.41m | 1.04bn | 3.59k | 15.23 | 4.78 | 13.83 | 4.54 | 38.07 | 38.07 | 127.71 | 121.26 | 0.9956 | 3.28 | 6.15 | 1,111,173,000.00 | 29.68 | 26.42 | 32.05 | 30.33 | 58.42 | 55.93 | 29.81 | 28.33 | 6.29 | 37.82 | 0.0009 | 95.17 | -7.75 | 5.23 | -13.95 | 7.45 | -27.13 | 11.37 |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 421.33k | 3.55% |
| Oddo BHF Asset Management SASas of 30 Aug 2024 | 323.42k | 2.72% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 267.01k | 2.25% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 137.77k | 1.16% |
| BNP Paribas Asset Management Europe SASas of 30 Sep 2024 | 123.54k | 1.04% |
| Cov�a Finance SASas of 30 Sep 2024 | 92.60k | 0.78% |
| Danske Bank A/S (Investment Management)as of 31 Oct 2024 | 78.30k | 0.66% |
| Janus Henderson Investors UK Ltd.as of 30 Sep 2024 | 60.67k | 0.51% |
| Amundi Asset Management SA (Investment Management)as of 30 Aug 2024 | 59.30k | 0.50% |
| Fourton Fund Management Co. Ltd.as of 30 Jun 2024 | 33.00k | 0.28% |
